321 related articles for article (PubMed ID: 30528592)
1. Motivation for participating in phase 1 vaccine trials: Comparison of an influenza and an Ebola randomized controlled trial.
Cattapan A; Browne K; Halperin DM; Di Castri A; Fullsack P; Graham J; Langley JM; Taylor BA; McNeil SA; Halperin SA
Vaccine; 2019 Jan; 37(2):289-295. PubMed ID: 30528592
[TBL] [Abstract][Full Text] [Related]
2. Volunteer feedback and perceptions after participation in a phase I, first-in-human Ebola vaccine trial: An anonymous survey.
Dayer JA; Siegrist CA; Huttner A
PLoS One; 2017; 12(3):e0173148. PubMed ID: 28273130
[TBL] [Abstract][Full Text] [Related]
3. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.
ElSherif MS; Brown C; MacKinnon-Cameron D; Li L; Racine T; Alimonti J; Rudge TL; Sabourin C; Silvera P; Hooper JW; Kwilas SA; Kilgore N; Badorrek C; Ramsey WJ; Heppner DG; Kemp T; Monath TP; Nowak T; McNeil SA; Langley JM; Halperin SA;
CMAJ; 2017 Jun; 189(24):E819-E827. PubMed ID: 28630358
[TBL] [Abstract][Full Text] [Related]
4. Controversial Ebola vaccine trials in Ghana: a thematic analysis of critiques and rebuttals in digital news.
Kummervold PE; Schulz WS; Smout E; Fernandez-Luque L; Larson HJ
BMC Public Health; 2017 Aug; 17(1):642. PubMed ID: 28784109
[TBL] [Abstract][Full Text] [Related]
5. Altruism among participants in cancer clinical trials.
Truong TH; Weeks JC; Cook EF; Joffe S
Clin Trials; 2011 Oct; 8(5):616-23. PubMed ID: 21813584
[TBL] [Abstract][Full Text] [Related]
6. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
[TBL] [Abstract][Full Text] [Related]
7. "We are the heroes because we are ready to die for this country": Participants' decision-making and grounded ethics in an Ebola vaccine clinical trial.
Tengbeh AF; Enria L; Smout E; Mooney T; Callaghan M; Ishola D; Leigh B; Watson-Jones D; Greenwood B; Larson H; Lees S
Soc Sci Med; 2018 Apr; 203():35-42. PubMed ID: 29544144
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
Zhu FC; Wurie AH; Hou LH; Liang Q; Li YH; Russell JB; Wu SP; Li JX; Hu YM; Guo Q; Xu WB; Wurie AR; Wang WJ; Zhang Z; Yin WJ; Ghazzawi M; Zhang X; Duan L; Wang JZ; Chen W
Lancet; 2017 Feb; 389(10069):621-628. PubMed ID: 28017399
[TBL] [Abstract][Full Text] [Related]
9. Participant Retention in a Randomized Clinical Trial in an Outbreak Setting: Lessons From the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE).
Carter RJ; Senesi RGB; Dawson P; Gassama I; Kargbo SAS; Petrie CR; Rogers MH; Samai M; Luman ET
J Infect Dis; 2018 May; 217(suppl_1):S65-S74. PubMed ID: 29788348
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing participation in an Ebola vaccine trial among front-line workers in Guinea.
Grantz KH; Claudot P; Kambala M; Kouyaté M; Soumah A; Boum Y; Juan-Giner A; Jemmy JP; Cummings DAT; Grais RF
Vaccine; 2019 Nov; 37(48):7165-7170. PubMed ID: 31623917
[TBL] [Abstract][Full Text] [Related]
11. Implementing a Multisite Clinical Trial in the Midst of an Ebola Outbreak: Lessons Learned From the Sierra Leone Trial to Introduce a Vaccine Against Ebola.
Carter RJ; Idriss A; Widdowson MA; Samai M; Schrag SJ; Legardy-Williams JK; Estivariz CF; Callis A; Carr W; Webber W; Fischer ME; Hadler S; Sahr F; Thompson M; Greby SM; Edem-Hotah J; Momoh RM; McDonald W; Gee JM; Kallon AF; Spencer-Walters D; Bresee JS; Cohn A; Hersey S; Gibson L; Schuchat A; Seward JF
J Infect Dis; 2018 May; 217(suppl_1):S16-S23. PubMed ID: 29788343
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.
Kibuuka H; Berkowitz NM; Millard M; Enama ME; Tindikahwa A; Sekiziyivu AB; Costner P; Sitar S; Glover D; Hu Z; Joshi G; Stanley D; Kunchai M; Eller LA; Bailer RT; Koup RA; Nabel GJ; Mascola JR; Sullivan NJ; Graham BS; Roederer M; Michael NL; Robb ML; Ledgerwood JE;
Lancet; 2015 Apr; 385(9977):1545-54. PubMed ID: 25540891
[TBL] [Abstract][Full Text] [Related]
13. Attitudes about vaccines to prevent Ebola virus disease in Guinea at the end of a large Ebola epidemic: Results of a national household survey.
Irwin KL; Jalloh MF; Corker J; Alpha Mahmoud B; Robinson SJ; Li W; James NE; Sellu M; Jalloh MB; Diallo AA; Tracy L; Hajjeh R; VanSteelandt A; Bunnell R; Martel L; Raghunathan PL; Marston B;
Vaccine; 2017 Dec; 35(49 Pt B):6915-6923. PubMed ID: 28716555
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
15. Qualitative study investigating the underlying motivations of healthy participants in phase I clinical trials.
Manton KJ; Gauld CS; White KM; Griffin PM; Elliott SL
BMJ Open; 2019 Jan; 9(1):e024224. PubMed ID: 30647042
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia.
Dolzhikova IV; Zubkova OV; Tukhvatulin AI; Dzharullaeva AS; Tukhvatulina NM; Shcheblyakov DV; Shmarov MM; Tokarskaya EA; Simakova YV; Egorova DA; Scherbinin DN; Tutykhina IL; Lysenko AA; Kostarnoy AV; Gancheva PG; Ozharovskaya TA; Belugin BV; Kolobukhina LV; Pantyukhov VB; Syromyatnikova SI; Shatokhina IV; Sizikova TV; Rumyantseva IG; Andrus AF; Boyarskaya NV; Voytyuk AN; Babira VF; Volchikhina SV; Kutaev DA; Bel'skih AN; Zhdanov KV; Zakharenko SM; Borisevich SV; Logunov DY; Naroditsky BS; Gintsburg AL
Hum Vaccin Immunother; 2017 Mar; 13(3):613-620. PubMed ID: 28152326
[TBL] [Abstract][Full Text] [Related]
17. Enrolling study personnel in Ebola vaccine trials: from guidelines to practice in a non-epidemic context.
Lhomme E; Modet C; Augier A; Faye S; Dabakuyo-Yonli TS; Levy-Marchal C; D'Ortenzio E; Yazdanpanah Y; Chêne G; Beavogui AH; Richert L;
Trials; 2019 Jul; 20(1):422. PubMed ID: 31296253
[TBL] [Abstract][Full Text] [Related]
18. Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries.
Badio M; Lhomme E; Kieh M; Beavogui AH; Kennedy SB; Doumbia S; Leigh B; Sow SO; Diallo A; Fusco D; Kirchoff M; Termote M; Vatrinet R; Wentworth D; Esperou H; Lane HC; Pierson J; Watson-Jones D; Roy C; D'Ortenzio E; Greenwood B; Chêne G; Richert L; Neaton JD; Yazdanpanah Y;
Trials; 2021 Jan; 22(1):86. PubMed ID: 33485369
[TBL] [Abstract][Full Text] [Related]
19. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
Li JX; Hou LH; Meng FY; Wu SP; Hu YM; Liang Q; Chu K; Zhang Z; Xu JJ; Tang R; Wang WJ; Liu P; Hu JL; Luo L; Jiang R; Zhu FC; Chen W
Lancet Glob Health; 2017 Mar; 5(3):e324-e334. PubMed ID: 28017642
[TBL] [Abstract][Full Text] [Related]
20. Under consent: participation of people with HIV in an Ebola vaccine trial in Canada.
David PM; Mathiot B; Thiongane O; Graham JE
BMC Med Ethics; 2021 Apr; 22(1):42. PubMed ID: 33836725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
